This TKI drug binds to several TK receptors, which are often over expressed in a lot of cancer cell types, including hepatocyte growth factor receptor (MET), RET (rearranged during transfection), and simultaneously inhibits angiogenic factor receptor as VEGFR-1, VEGFR-2, and VEGFR-3. The gene discussed is KDR; the disease is cancer.